Has Jaspreet Kaler, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,605 in general payments to Jaspreet Kaler, MD across 78 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jaspreet Kaler, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jaspreet Kaler, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jaspreet Kaler, MD

Rheumatology · Kennewick, WANPI 1558745083

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 27.5% of the total. Reporting peaked in 2021 at $534 and has fallen 97.4% since, to $14 in 2024.

$1,605in general payments, 2019–2025

Across 78 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$442
Amgen$363
Novartis$231
AstraZeneca$144
E.r. Squibb & Sons, L.L.C.$133
Genentech USA, Inc.$52
plus $240 from 9 others

$8,964in research payments, 2019–2025

Across 6 payments — averaging $1493.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$5K
Novartis$4K

What the payments were for

Food & beverage$1,605100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	17	$442
Amgen	23	$363
Novartis	11	$231
AstraZeneca	3	$144
E.r. Squibb & Sons, L.L.C.	7	$133
Genentech USA, Inc.	3	$52
GSK	3	$46
Pfizer	3	$45
Antares Pharma, Inc.	2	$35
Aurinia Pharma U.S., Inc.	1	$26
Johnson & Johnson	1	$22
Sobi, Inc	1	$20
Actelion Pharmaceuticals US, Inc.	1	$19
UCB, Inc.	1	$14
Lilly USA, LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,605 in reported general payments places this provider in the 65th percentile of 157 rheumatology providers in Washington.

See all rheumatology providers in Washington →

Medicare billing

Part B allowed, 2024

$55,623

Medicare patients

302

Services billed

875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Enbrel SureclickEtanercept	23	$167,074
Humira(Cf) PenAdalimumab	24	$166,077
Orencia ClickjectAbatacept	18	$104,962
Taltz AutoinjectorIxekizumab	13	$89,336
Hydroxychloroquine Sulfate	285	$15,937
MethotrexateMethotrexate Sodium	152	$4,858
Leflunomide	43	$3,522
Cevimeline Hcl	18	$2,536
Pilocarpine Hcl	20	$2,467
Sulfasalazine	19	$1,332
Celecoxib	37	$1,191
Sulfasalazine DrSulfasalazine	19	$980
Diclofenac Sodium	12	$880
Prednisone	145	$779
Allopurinol	33	$592

Paid to pharmacies, not to this prescriber.

Other rheumatology in Kennewick

Sandra Horvath DoriKennewick$2K
Stanford PengSeattle$3.5M
Jeff PetersonBothell$2.3M
Philip MeaseSeattle$2.1M
Robert EttlingerTacoma$232K
Richard JimenezBothell$155K
Howard KenneySpokane$132K
Arinola DadaBellevue$69K
Verlene GauthierCovington$63K
Jane BucknerSeattle$57K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →